California State Teachers Retirement System Cuts Stake in DaVita Inc. (NYSE:DVA)

California State Teachers Retirement System reduced its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 22.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,914 shares of the company's stock after selling 19,580 shares during the period. California State Teachers Retirement System owned about 0.08% of DaVita worth $9,857,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DVA. Copia Wealth Management acquired a new position in shares of DaVita in the 4th quarter valued at $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of DaVita in the fourth quarter valued at about $41,000. Coppell Advisory Solutions LLC raised its holdings in shares of DaVita by 50.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after buying an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan purchased a new stake in shares of DaVita in the fourth quarter valued at about $55,000. Finally, Venturi Wealth Management LLC grew its stake in shares of DaVita by 59.8% in the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after purchasing an additional 152 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Barclays increased their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. Truist Financial cut their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Finally, Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $164.50.

DaVita Price Performance

NYSE DVA traded up $1.83 during trading hours on Wednesday, reaching $137.82. The company's stock had a trading volume of 226,363 shares, compared to its average volume of 818,945. The stock has a market cap of $10.41 billion, a PE ratio of 12.83, a PEG ratio of 1.07 and a beta of 1.11. DaVita Inc. has a fifty-two week low of $131.76 and a fifty-two week high of $179.60. The company's 50-day moving average is $143.42 and its two-hundred day moving average is $152.51. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The company had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. During the same period last year, the company earned $2.26 EPS. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. Analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.